I
nvasive pneumococcal disease (IPD) is a serious bacterial infection caused by the bacteria Streptococcus pneumoniae and can result in bacteraemia, meningitis and pneumonia. Higher rates of the disease are seen in children less than two years of age, in older adults and in people who are immunosuppressed or have a chronic illness.
1
There are 90 known capsular antigenic types of S. pneumoniae. Some serotypes are carried in the upper respiratory tract and others are more associated with the invasive disease. Prior to the introduction of pneumococcal vaccines into the Australian immunization schedule, 83%-85% of IPD cases in children aged less than 14 years and 69% of IPD cases in adults aged more than 65 years in the state of New South Wales (NSW) could be attributed to the seven serotypes found in the 7-valent pneumococcal conjugate vaccine (7vPCV) (Box 1). 2 Changes in invasive pneumococcal disease serotypes in a regional area of Australia following three years of 7vPCV introduction A vaccine programme has been in place in Australia for pneumococcal disease since 1999 when the 23-valent polysaccharide pneumococcal vaccine (23vPPV) was introduced for Aboriginal and Torres Strait Islander adults aged 50 years and over (Box 2). 1 This was extended to non-Aboriginal people from 2005 for those aged 65 years and over. The vaccine is also recommended for people less than 65 years of age who have conditions that predispose them to IPD. Fitzgerald et al. Invasive pneumococcal disease serotypes after three years of PCV7 introduction study estimated that a further 64% of IPD cases could be prevented by the introduction of 13vPCV through direct and indirect effects. Different areas across Australia likely have different IPD epidemiology.
The Hunter New England Local Health District has a population of approximately 840 000 and consists of both rural and urban landscapes over 130 000 km 2 . Approximately 22% of the NSW Aboriginal and Torres Strait Islander population reside in this area. The proportion of the population aged 65 years and over is approximately 17% and is projected to increase to 25% by 2030.
5
The aim of this investigation was to describe the notification rates of IPD before and after the introduction of the vaccine programmes, in a regional area in the state of New South Wales, Australia. An additional aim was to explore changes in the distribution of serotypes of the notified cases in relation to the available vaccines. There have been some reports of the impact of the pneumococcal vaccine since its introduction into the Australian immunization schedule and the potential benefits that may be offered by the 13vPVC. A national study of IPD in children less than two years old reported a 74% decline in incidence of IPD post introduction of the pneumococcal vaccine in 2005 with a 97% decline in cases caused by 7vPCV types.
METHODS
3 At that time, 50%
of IPD cases were caused by serotypes contained in 13vPCV.
In the regional area of North Queensland, IPD rates have declined by 34% across all age groups after introduction of 7vPVC. Declines in the number of IPD cases caused by serotypes contained in 7vPCV across age groups not targeted for vaccination demonstrated that 7vPCV had a population effect. 4 The authors of this Invasive pneumococcal disease serotypes after three years of PCV7 introduction Fitzgerald et al.
The overall notification rate in males was greater than females at 16.6 per 100 000 and 9.3 per 100 000, respectively, in the period 2002-2004 and 10.0 per 100 000 in males and 6.2 per 100 000 in females in the period 2008-2010. The largest decline was observed in notifications of IPD cases caused by 7vPCV serotypes with a rate ratio of 0.17 (95% CI: 0.12-0.24). A decline was also observed in the notification rate of IPD caused by 23PPV types (RR, 0.55, 95% CI: 0.45-0.67).
An increase was observed in the notification rate of IPD cases with 23PPV only types (RR, 1.99, 95% CI: 1.43-2.73). The notification rate of IPD with non-vaccine types also increased with a RR of 3.18 (95% CI: 1.84-5.49). An increase was noted in IPD cases caused by 6v (13v-7v) types (RR, 2.43, 95% CI: 1.61-3.66). In fact, 40.6% of cases in the zero to four years age group were caused by 6v (13v-7v) types ( Table 1 ).
Significant increases were recorded for 23PPV only, non-7vPCV and 6V(13v-7v) types in the 0-4, 15-64 and 65+ years age groups. Additionally, there was also a significant increase for non-vaccine types in the 15-64 and 65+ years age groups. Significant decreases were seen in the total, 23PPV and 7vPCV types for these age groups. There was no significant difference between the notification rates of IPD for 5 to 14- Serotypes were grouped into 7vPCV, 23vPPV, 23PPV-only (16 serotypes) and non-vaccine types. Serotypes not contained in any pneumococcal vaccine were termed non-vaccine types. The additional six serotypes found in 13vPCV are also described (referred to as 6v [13v-7v]).
This project was deemed a quality improvement exercise by the HNE Human Research Ethics Committee and did not require ethics approval.
RESULTS
The total number of laboratory-confirmed IPD cases for the The increase in incidence of 23vPPV-only types across all age groups and less than 60% immunization coverage in the greater than 65 years age group suggests that 23vPPV has provided individual protection rather than a population effect.
8
Increased nasopharyngeal carriage of 23vPPV-only types in vaccinated children may have had a negative effect on the impact of 23vPPV. 4 Varied immunogenicity in the greater than 65 years age group due to comorbidities may have also had a negative impact on the efficacy of 23PPV.
DISCUSSION
This investigation supports other reports that show the decline in the notification rate of IPD in children can be directly attributed to the use of 7vPCV. 6 The decline in notification rates in adults is most likely an indirect effect of 7vPCV programme in children. 7 This is supported by the recorded increase in the notification rate of IPD caused by 23vPPV-only types across most age groups. A similar effect has been described in another regional area of Australia 4 and internationally. Note: 23vPPV only = 23vPPV -7vPCV; non-7vPCV = total -(7vPCV + untyped); and non-vaccine = total -(23PPV + untyped).
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coverage are associated with increases in non-vaccine types.
10
No changes were made to surveillance or to IPD treatment protocols during the study periods. This study is also limited by the quality of the current surveillance system where several factors affect the notifiable fraction for communicable diseases in rural and regional areas in Australia, such as decreased seeking of medical care and decreased collection and submission of specimens.
14 No outbreaks of IPD were recorded during this time.
CONCLUSION
The 7vPCV has proven to be an effective health intervention in reducing the pneumococcal disease burden in a regional area of Australia despite some level of serotype replacement. There is a potential for continuous serotype replacement after the introduction of 13vPCV as has happened with 7vPCV, but as with 7vPCV, the gains made with 13vPCV are likely to improve health outcomes for both children and adults. The increase in cases due to serotypes in 13vPCV implies that 13vPCV presents an opportunity to further reduce the burden of IPD in the Hunter New England Local Health District.
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The increase in non-vaccine serotypes across all age groups is consistent with the phenomenon of serotype replacement that has been described elsewhere.
10
Serotype 19A has emerged as a potent disease-causing organism, with its capsular switching and increasing antibiotic resistance, it has been able to evade vaccine selection pressure.
11 Serotype 19A is one of the serotypes contained in the newly introduced 13vPCV. If the distribution of serotypes remains the same, there is potential for a further 21% decline in the incidence of IPD caused by 19A in adults in the study population through a population effect.
The 13vPCV also presents an opportunity to further reduce the burden of IPD in children. In the zero to four year age group, 40.6% of all notified IPD cases during the 2008-2010 period were caused by 6v (13v-7v) types. This result is similar to the findings of a national study in 2007.
3
IPD rates in males were observed to be higher than that of females. This phenomenon was observed across all age groups in both comparison periods and has been documented elsewhere. 12 Continued surveillance of IPD is essential in monitoring the impacts of the pneumococcal vaccines and trends in serotypes.
There are limitations to this study. The decline in 6v(13v-7v) types in the 5-14 years age group differs to trends in other age groups and may represent lack of precision with relatively small numbers. However, our findings of a population effect due to the 7vPCV are consistent with findings from another regional area of Australia, in North Queensland.
3,4
The 35% decline in IPD notification rates in the 15-64 year age group is markedly different to the 2.6% decline found in North Queensland. This may be explained by the difference in study periods. The study period 2008-2010 is later than the 2006-2009 study period in north Queensland, which may have given 7vPCV more time to impact the population. Regional differences in serotypes and immunization rates may also have an impact and limit the ability of this study to be extrapolated to other regional areas of Australia.
10
Pneumococcal vaccine coverage in the Hunter New England Local Health District before the introduction of the funded programmes in 2005 is unknown. Over 95% of children aged 24-27 months in HNE were immunized in the 2008-2010 study period. 13 High immunization
